title: Typing of killer-cell immunoglobulin-like receptors and their cognate human leukocyte antigen class I ligands predicts survival of Chinese Han patients with metastatic non-small-cell lung cancer.
abstract: Non-small-cell lung cancer (NSCLC) may establish an immunosuppressive tumor microenvironment that is conducive to tumor growth. Natural killer (NK) cells play a pivotal role in immunological surveillance. Activation of NK cells partially depends on the interactions between killer-cell immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I ligands. We herein investigated the association of KIRs and HLA ligands with survival in metastatic NSCLC (mNSCLC) patients treated with chemotherapy in a Chinese Han population. Polymerase chain reaction with sequence-specific primers was used to type 15 KIRs at the DNA and mRNA level and 6 HLA ligands in 70 mNSCLC patients. Survival curves were estimated using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazard regression model was applied for multivariate survival analysis, with the stepwise selection, to determine independent predictors of survival. It was observed that patients with KIR2DS4del gene expression at the mRNA level or HLA-Bw4T80 exhibited poor overall survival (OS). The multivariate analysis revealed that HLA-Bw4T80 and KIR2DS4del expression were independent predictors of OS. This observation indicated that the KIR/HLA ligand is a promising predictor of survival in mNSCLC and may also provide a strategy for treatment stratification and patient management.
authors.affiliation: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Yu
authors.affiliation: Fudan University Shanghai Cancer Center-Institut Mérieux Laboratory, Shanghai 200032, P.R. China; Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd., Shanghai 201315, P.R. China.
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.affiliation: Transgene S.A., 67405 Illkirch Graffenstaden, France.
authors.forename: Benoit
authors.initials: B
authors.lastname: Sansas
authors.affiliation: Fudan University Shanghai Cancer Center-Institut Mérieux Laboratory, Shanghai 200032, P.R. China.
authors.forename: Bin
authors.initials: B
authors.lastname: Kang
authors.affiliation: Transgene S.A., 67405 Illkirch Graffenstaden, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Preville
authors.affiliation: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.
authors.forename: Xianghua
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Chang
authors.affiliation: Transgene S.A., 67405 Illkirch Graffenstaden, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Micol
authors.affiliation: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.
authors.forename: Jialei
authors.initials: J
authors.lastname: Wang
authors.affiliation: Fudan University Shanghai Cancer Center-Institut Mérieux Laboratory, Shanghai 200032, P.R. China; Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd., Shanghai 201315, P.R. China.
authors.forename: Xia
authors.initials: X
authors.lastname: Meng
keywords: human leukocyte antigen; killer-cell immunoglobulin-like receptor; non-small-cell lung cancer; prognosis